[{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"summary","before":"\"Guardant Health. ECLIPSE: 83% sensitivity for CRC, 13% for advanced adenomas, 90% specificity. Medicare coverage. Shield MCD (multi-cancer) option added 2025 with Breakthrough designation.\"","after":"\"Shield is Guardant Health's blood-based colorectal cancer screening test. ECLIPSE: 83% sensitivity for CRC, 13% for advanced adenomas, 90% specificity. Medicare coverage. Shield MCD (multi-cancer) option added 2025 w..."}]},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/drugs.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"modality"},{"field":"asOf"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"approvals"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"}]}]